Kinetics studies of the cardiac Ca-ATPase expressed in Sf21 cells (Spodoptera frugiperda insect cells) have been carried out to test the hypotheses that phospholamban inhibits Ca-ATPase cycling by decreasing the rate of the E1·Ca to E1'·Ca transition and/or the rate of phosphoenzyme hydrolysis. Three sample types were studied: Ca-ATPase expressed alone, Ca- ATPase coexpressed with wild-type phospholamban (the natural pentameric inhibitor), and Ca-ATPase coexpressed with the L37A-phospholamban mutant (a more potent monomeric inhibitor, in which Leu37 is replaced by Ala). Phospholamban coupling to the Ca-ATPase was controlled using a monoclonal antibody against phospholamban. Gel electrophoresis and immunoblotting confirmed an equivalent ratio of Ca-ATPase and phospholamban in each sample (1 mol Ca-ATPase to 1.5 mol phospholamban). Steady-state ATPase activity assays at 37°C, using 5 mM MgATP, showed that the phospholamban-containing samples had nearly equivalent maximum activity (~0.75 (max)mol·nmol Ca- ATPase-1·min-1 at 15 μM Ca2+), but that wild-type phospholamban and L37A-phospholamban increased the Ca-ATPase K(Ca) values by 200 nM and 400 nM, respectively. When steady-state Ca-ATPase phosphoenzyme levels were measured at 0°C, using 1 μM MgATP, the K(Ca) values also shifted by 200 nM and 400 nM, respectively, similar to the results obtained by measuring ATP hydrolysis at 37°C. Measurements of the time course of phosphoenzyme formation at 0°C, using 1 μM MgATP and 268 nM ionized [Ca2+], indicated that L37A- phospholamban decreased the steady-state phosphoenzyme level to a greater extent (45%) than did wild-type phospholamban (33%), but neither wild-type nor L37A-phospholamban had any effect on the apparent rate of phosphoenzyme formation relative to that of Ca-ATPase expressed alone. Measurements of inorganic phosphate (P(i)) release concomitant with the phosphoenzyme formation studies showed that L37A-phospholamban decreased the steady-state rate of P(i) release to a greater extent (45%) than did wild-type phospholamban (33%). However, independent measurements of Ca-ATPase dephosphorylation after the addition of 5 mM EGTA to the phosphorylated enzyme showed that neither wild-type phospholamban nor L37A-phospholamban had any effect on the rate of phosphoenzyme decay relative to Ca-ATPase expressed alone. Computer simulation of the kinetics data indicated that phospholamban and L37A-phospholamban decreased twofold and fourfold, respectively, the equilibrium binding of the first Ca2+ ion to the Ca-ATPase E1 intermediate, rather than inhibiting rate of the E·Ca to E'·Ca transition or the rate of phosphoenzyme decay. Therefore, we conclude that phospholamban inhibits Ca- ATPase cycling by decreasing Ca-ATPase Ca2+ binding to the E1 intermediate.
Bibliographical noteFunding Information:
This work was supported by the American Heart Association, WV-OH Affiliate (grant-in-aid WV-97-07-B to JEM), and the National Institutes of Health (grant HL49428 to LRJ).
Copyright 2017 Elsevier B.V., All rights reserved.